Filana Therapeutics, Inc.
NASDAQ:FLNA · NASDAQ Global Market
+$0.02 today
Vol 0.42M · Avg 0.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-122.3%
avg -24.5%
ROIC
-128.0%
avg -25.6%
ROA
-76.9%
avg -15.4%
Analysis
ROA is currently the strongest return metric at -76.9% versus its period average of -15.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard Jon Barry | CEO, President & Director | $1.03M | — | 67 | — | — |
Eric J. Schoen | Chief Financial Officer | $690,000.00 | — | 58 | — | — |
R. Christopher Cook | Chief Operating & Legal Officer | $678,975.00 | — | 62 | — | — |
Angelique Bordey | Senior Vice President of Neuroscience | — | — | — | — | — |
George Thornton | Senior Vice President of Technology | — | — | — | — | — |
Joseph Hulihan | Chief Medical Officer | — | — | 69 | — | — |
Jaren Landen | Chief Clinical Development Officer | — | — | — | — | — |
Jack Moore | Senior Vice President of Clinical Development | — | — | — | — | — |
Michael Zamloot | Senior Vice President of Technical Operations | — | — | — | — | — |
Freda Nassif | Chief Business Officer & Chief Commercial Officer | — | — | 49 | — | — |
Nancy Teasdale | Head of Regulatory Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages FLNA?
Filana Therapeutics, Inc. (FLNA) lists 11 active executives. The top listed executive is R. Christopher Cook, Chief Operating & Legal Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.